How to Control Impurities during API drug manufacturing
Posted: February 19, 2018
Dr. Rajesh Shukla, Vice President Research and Development at PCI Synthesis Talks about Controlling Impurities during API drug manufacturing.
Related posts:
Seqens North America Honored with CMO Leadership Award for Reliability – Part 1
Did Your API Project Exceed Budget? Here’s Why
Easing Process Validation Rules for Small-Volume Manufacturers Might Be First Step in Easing Drug S...
Why Does the U.S. Continue to Lead the Contract Manufacturing Market?
With New Chemical Entities the Only Constant is Change
About the Author
Ed is President & CEO of SEQENS North America (formerly PCI Synthesis). He serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA)...